Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maplirpacept Monotherapy in Chinese Participants with Advanced Hematologic Malignancies
NCT05896774Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Nov 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of maplirpacept in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose-Limiting Toxicity, Single-dose Maximum Observed Plasma Concentration at Day 8 and 2 more. Started Jun 2023; status: completed.
02
Drugs
maplirpacept
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05896774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896774.